In colorectal cancer (CRC) and bladder cancer (BC), METTL3 accelerates the cell cycle of tumor cells by directly promoting the expressions of CCNE1 [45], AF4/FMR2 family member 4 (AFF4), two key regulators of the NF-κB pathway (IKBKB and RELA), and MYC [46]. Here, METTL3 is linked to urinary bladder cancer.